L'intérêt à découvert pour Lantheus Holdings donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Lantheus Holdings. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Lantheus Holdings (NASDAQ:LNTH) Stock, Rapport sur les intérêts à découvert

LANTHEUS HOLDINGS INC

Lantheus Holdings

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Lantheus Holdings Inc

Truist Securities analyst Richard Newitter maintains Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Buy and lowers the price target from $127 to $117.

News

Price Target

Analyst Ratings

LNTH

Truist Securities Maintains Buy on Lantheus Holdings, Lowers Price Target to $117

U.S. stock futures were higher this morning, with the Dow futures gaining over 300 points on Wednesday.
Shares of Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) fell sharply in today's pre-market trading after the company <a href="https://www.benzinga.com/quote/SRPT/earnings">reported a first-quarter adjusted EPS miss.</a>
Therapeutics reported quarterly losses of $3.42 per share, which missed the analyst consensus estimate of losses of 95 cents. Quarterly revenue came in at $744.86 million, which beat the consensus estimate of $683.36 million.
Sarepta Therapeutics lowered its fiscal 2025 revenue to a new range of $2.3 billion to $2.6 billion.
Sarepta Therapeutics shares tumbled 20.6% to $37.10 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Vestis Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSTS#NYSE">VSTS</a>) fell 25.7% to $6.47 in pre-market trading after the company reported worse-than-expected quarterly financial results.</li>
<li>Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) fell 16.2% to $43.09 in pre-market trading after the company issued second-quarter sales guidance below estimates.</li>
<li>Apellis Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) dipped 13.6% to $16.53 in pre-market trading following first-quarter results.</li>
<li>Revolve Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVLV#NYSE">RVLV</a>) fell 10.8% to $16.90 in today's pre-market trading after the company reported downbeat quarterly sales.</li>
<li>The Hackett Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCKT#NASDAQ">HCKT</a>) dipped 8.9% to $23.69 in pre-market trading after the company issued weak outlook for the second quarter.</li>
<li>RXO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RXO#NYSE">RXO</a>) fell 7.6% to $12.70 in pre-market trading.</li>
<li>Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) dipped 7% to $56.94 in pre-market trading after the company postponed its Investor Day amid uncertainty.</li>
<li>Lantheus Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) declined 6.5% to $98.06 in pre-market trading after the company posted downbeat first-quarter results and lowered its FY25 forecast.</li>
<li>Mercury Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRCY#NASDAQ">MRCY</a>) fell 5.7% to $47.54 in pre-market trading following weaker-than-expected quarterly earnings.</li>
<li>Arista Networks Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) dipped 5.3% to $86.00 in pre-market trading following downbeat quarterly sales.  </li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45219636/top-2-energy-stocks-that-are-ticking-portfolio-bombs">Top 2 Energy Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Movers

Trading Ideas

ANET

APLS

HCKT

MRCY

MRVL

RVLV

SRPT

UPST

VSTS

Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares increased by 88.9% to $2.57 during Wednesday's pre-market session. The market value of their outstanding shares is at $7.1 million. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) stock moved upwards by 45.13% to $0.8. The company's market cap stands at $2.8 million. </li>
<li>Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) shares moved upwards by 21.56% to $140.3. The company's market cap stands at $7.1 billion. As per the press release, Q1 earnings came out today. </li>
<li>Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) shares rose 21.09% to $22.11. The market value of their outstanding shares is at $389.4 million. The company's, Q1 earnings came out yesterday. </li>
<li>Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) stock rose 19.56% to $3.85. The market value of their outstanding shares is at $21.5 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares moved upwards by 17.68% to $0.56. The company's market cap stands at $6.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock decreased by 55.0% to $0.08 during Wednesday's pre-market session. The company's market cap stands at $1.9 million. </li>
<li>Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) stock decreased by 24.35% to $5.5. The company's market cap stands at $506.9 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) stock decreased by 20.22% to $0.75. The company's market cap stands at $2.9 million. </li>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) stock declined by 18.08% to $38.3. The company's market cap stands at $3.7 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Geron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) stock decreased by 14.41% to $1.13. The market value of their outstanding shares is at $719.6 million. As per the press release, Q1 earnings came out today. </li>
<li>Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) shares fell 12.54% to $91.7. The company's market cap stands at $6.2 billion. The company's, Q1 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GERN

KZIA

MYGN

RIGL

TOVX

ZVSA

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

WIIM

Lantheus Holdings shares are trading lower after the company reported worse-than-expected Q1 financial results and cut its FY25 guidance below estimates.

Full Year 2025 Interim Corporate Financial Guidance
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Guidance Issued May 7, 2025</td>
<td>Guidance Issued February 26, 2025</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>FY 2025 Revenue</td>
<td>$1.550 billion - $1.585 billion</td>
<td>$1.545 billion - $1.610 billion</td>
</tr>
<tr>
<td>FY 2025 Adjusted fully diluted EPS</td>
<td>$6.60 - $6.70</td>
<td>$7.00 - $7.20</td>
</tr>
</tbody>
</table>
</figure>

Guidance

Lantheus Lowers FY25 Outlook: Adj EPS From $7.00-$7.20 To $6.60-$6.70 Vs $7.08 Estimate; Sales From $1.54B-$1.61B To $1.55B-$1.58B vs $1.59B Estimate

Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) reported quarterly earnings of $1.53 per share which missed the analyst consensus estimate of $1.66 by 7.83 percent. This is a 9.47 percent decrease over earnings of $1.69 per share from the same period last year. The company reported quarterly sales of $372.64 million which missed the analyst consensus estimate of $379.02 million by 1.68 percent. This is a 0.72 percent increase over sales of $369.98 million the same period last year.

Earnings

Earnings Misses

Lantheus Holdings Q1 Adj. EPS $1.53 Misses $1.66 Estimate, Sales $372.64M Miss $379.02M Estimate

ACAD

ACDC

ACRE

ACVA

ADMA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

ALVO

AMPH

AMPL

AMRK

AMRN

AOSL

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVDX

AXON

AXTA

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BRKR

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENT

CENTA

CENX

CEVA

CIVI

CMTG

CNDT

COHR

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRNC

CRNT

CSGS

CSTE

CTVA

CVNA

CYRX

Earnings Scheduled For May 7, 2025

Enables Lantheus to focus on innovative radiopharmaceuticals, while maximizing the value of its SPECT business
SHINE will acquire products TechneLite&#xAE;, NEUROLITE&#xAE;, Xenon Xe-133 Gas, and Cardiolite&#xAE;
BEDFORD, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced a definitive agreement to sell its single photon emission computed tomography (SPECT) business to Illuminated Holdings, Inc., the parent company of SHINE Technologies, LLC (collectively, "SHINE"). Under the terms of the agreement, SHINE will acquire Lantheus' SPECT business, including its diagnostic agents (TechneLite&#xAE; (Technetium Tc 99m generator), NEUROLITE&#xAE; (Kit for the Preparation of Technetium Tc 99m Bicisate for Injection), Xenon Xe-133 Gas (Xenon Xe-133 Gas), and Cardiolite&#xAE; (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection)), the portion of the North Billerica, Massachusetts campus that manufactures Lantheus' SPECT products, and the SPECT-related Canadian operations.
The transaction allows Lantheus to focus on growing its commercial portfolio of innovative PET radiodiagnostics and microbubbles, while advancing its pipeline of radiopharmaceuticals. SHINE is a global leader in nuclear medicine production and, with its proven expertise in developing next-generation fusion and fusion-based technology and sustainable medical isotope supply chains, is the ideal partner to ensure the continuity and expansion of the SPECT business.
Under terms of the agreement, Lantheus will receive an upfront cash payment, a note convertible into SHINE preferred stock, and additional consideration, including potential earnout milestones. The transaction has been approved by the Boards of Directors of both companies and is expected to close by the end of the year, subject to customary closing conditions.

Lantheus Holdings Agrees To Sell Single Photon Emission Computed Tomography Business To Illuminated Holdings; Terms Not Disclosed

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>INO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/21/25</td>
<td>$2.00</td>
<td>$30.8K</td>
<td align="right">332</td>
<td>4.0K</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/02/25</td>
<td>$820.00</td>
<td>$35.4K</td>
<td align="right">141</td>
<td>1.1K</td>
</tr>
<tr>
<td>RARE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$45.00</td>
<td>$44.3K</td>
<td align="right">255</td>
<td>1.0K</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$182.50</td>
<td>$28.8K</td>
<td align="right">780</td>
<td>752</td>
</tr>
<tr>
<td>LNTH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$100.00</td>
<td>$81.1K</td>
<td align="right">468</td>
<td>324</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$165.00</td>
<td>$79.9K</td>
<td align="right">302</td>
<td>65</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$85.00</td>
<td>$34.1K</td>
<td align="right">236</td>
<td>59</td>
</tr>
<tr>
<td>PODD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$260.00</td>
<td>$35.7K</td>
<td align="right">5</td>
<td>10</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding INO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>), we observe a call option sweep with bearish sentiment. It expires in 204 day(s) on November 21, 2025. Parties traded 684 contract(s) at a $2.00 strike. This particular call needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $30.8K, with a price of $45.0 per contract. There were 332 open contracts at this strike prior to today, and today 4000 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option sweep with bearish sentiment. It expires in 1 day(s) on May 2, 2025. Parties traded 43 contract(s) at a $820.00 strike. This particular call needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $35.4K, with a price of $836.0 per contract. There were 141 open contracts at this strike prior to today, and today 1130 contract(s) were bought and sold. 
• For RARE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>), we notice a call option sweep that happens to be bullish, expiring in 106 day(s) on August 15, 2025. This event was a transfer of 80 contract(s) at a $45.00 strike. This particular call needed to be split into 24 different trades to become filled. The total cost received by the writing party (or parties) was $44.3K, with a price of $560.0 per contract. There were 255 open contracts at this strike prior to today, and today 1028 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a call option sweep that happens to be bearish, expiring in 15 day(s) on May 16, 2025. This event was a transfer of 22 contract(s) at a $182.50 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $28.8K, with a price of $1310.0 per contract. There were 780 open contracts at this strike prior to today, and today 752 contract(s) were bought and sold. 
• For LNTH (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>), we notice a put option sweep that happens to be bearish, expiring in 15 day(s) on May 16, 2025. This event was a transfer of 163 contract(s) at a $100.00 strike. This particular put needed to be split into 53 different trades to become filled. The total cost received by the writing party (or parties) was $81.1K, with a price of $500.0 per contract. There were 468 open contracts at this strike prior to today, and today 324 contract(s) were bought and sold. 
• For JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we notice a call option trade that happens to be bearish, expiring in 624 day(s) on January 15, 2027. This event was a transfer of 65 contract(s) at a $165.00 strike. The total cost received by the writing party (or parties) was $79.9K, with a price of $1230.0 per contract. There were 302 open contracts at this strike prior to today, and today 65 contract(s) were bought and sold. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a call option trade that happens to be bearish, expiring in 413 day(s) on June 18, 2026. This event was a transfer of 33 contract(s) at a $85.00 strike. The total cost received by the writing party (or parties) was $34.1K, with a price of $1035.0 per contract. There were 236 open contracts at this strike prior to today, and today 59 contract(s) were bought and sold. 
• For PODD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>), we notice a put option sweep that happens to be bullish, expiring in 260 day(s) on January 16, 2026. This event was a transfer of 10 contract(s) at a $260.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $35.7K, with a price of $3570.0 per contract. There were 5 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ABBV

PODD

RARE

8 Health Care Stocks Whale Activity In Today's Session

Lantheus Holdings, Inc.&nbsp;("Lantheus") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that its clinical-stage F18-labeled tau Positron Emission Tomography (PET) radiodiagnostic, MK-6240 (F18-florquinitau), successfully met its co-primary endpoints in two pivotal studies assessing its sensitivity and specificity. This achievement reinforces the potential of MK-6240 as a valuable diagnostic tool. The data from these two studies will support a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) expected to be filed in the third quarter of 2025.

Lantheus Holdings' Clinical-Stage F18-labeled tau PET Radiodiagnostic, MK-6240, Meets Co-primary Endpoints In Two Pivotal Studies Assessing Sensitivity And Specificity

A global collaboration agreement has been signed for the development and commercialization of a Granzyme B-targeted Positron Emission Tomography (PET) imaging radiotracer.
This radiotracer has the potential to support the monitoring of patient immune response and supports the accelerated development for CytoSite.
CytoSite will lead initial clinical development with Lantheus having an exclusive option to acquire worldwide development and commercialization rights to the radiotracer.
BOSTON, March 26, 2025 /PRNewswire/ -- CytoSite Bio (CytoSite) announced today that they have signed a collaboration agreement for the clinical development and potential commercialization of CytoSite's investigational Phase 1 ready granzyme B-targeted Positron Emission Tomography (PET) imaging tracer with Lantheus Holdings, Inc. This agreement provides Lantheus with an exclusive option to license worldwide rights to CytoSite's novel imaging technology.
The two companies will collaborate on clinical development, with Lantheus having the option to acquire exclusive worldwide rights for further development and commercialization of the product. Under the terms of the agreement, CytoSite is eligible to receive payments for development, regulatory and commercial milestones, plus royalties on future product sales.
Granzyme B is an enzyme released upon activation of immune cells to destroy harmful cells, including cancer. Early studies of the investigational imaging tracer have shown potential to evaluate whether immunotherapies are working effectively to activate the immune system. This investigational PET imaging radiotracer could enable physicians to measure the early efficacy of such therapies within days of first dose and modify treatment accordingly rather than waiting for months to fully understand if the treatment is working. Additionally, pharmaceutical developers can use the investigational imaging tracer to gain an early read-out of efficacy for new therapies, enabling faster decision-making and more efficient allocation of resources.

Biotech

General

CytoSite Bio Announces Agreement With Lantheus For Granzyme B Targeted PET Imaging Radiotracer For Immunotherapy Assessment; CytoSite Will Lead Initial Clinical Development With Lantheus Having An Exclusive Option To Acquire Worldwide Development And Commercialization Rights To The Radiotracer

B. Riley Securities analyst Justin Walsh maintains Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Buy and lowers the price target from $127 to $122.

B. Riley Securities Maintains Buy on Lantheus Holdings, Lowers Price Target to $122

These eight mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Root, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROOT#NASDAQ">ROOT</a>) stock gained 34.89% after the company reported <a href="https://www.benzinga.com//node/43993814" target="_blank" rel="noreferrer noopener">better-than-expected Q4</a> financial results. Wells Fargo raised the price forecast on the stock <a href="https://www.benzinga.com/quote/ROOT/analyst-ratings" target="_blank" rel="noreferrer noopener">from $80 to $97</a>.</li>
<li>Bridge Investment Group Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRDG#NYSE">BRDG</a>) shares jumped 32.45% after the company entered a deal to be acquired by Apollo Global Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) in an all-stock <a href="https://www.benzinga.com//node/43917364" target="_blank" rel="noreferrer noopener">transaction valued at around $1.5 billion</a>. Analysts revised the <a href="https://www.benzinga.com/quote/brdg/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast on the stock</a>.</li>
<li>Huron Consulting Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURN#NASDAQ">HURN</a>) shares rose 23.21% after the company reported better-than-<a href="https://www.benzinga.com//node/43956537" target="_blank" rel="noreferrer noopener">expected quarterly financial results</a>. Also, multiple firms raised their respective <a href="https://www.benzinga.com/quote/hurn/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast on the stock</a>.</li>
<li>Medical Properties Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPW#NYSE">MPW</a>) shares increased 21.15% after the company reported better-<a href="https://www.benzinga.com//node/44004172" target="_blank" rel="noreferrer noopener">than-expected financial results</a>.</li>
<li>ZoomInfo Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) stock escalated 20.83% after the company reported 2024 <a href="https://www.benzinga.com//node/43990629" target="_blank" rel="noreferrer noopener">fiscal-year fourth-quarter earnings</a>. Scotiabank analyst Allan Verkhovski maintained a Sector Perform rating and raised the price <a href="https://www.benzinga.com/quote/zi/analyst-ratings" target="_blank" rel="noreferrer noopener">forecast from $10.3 to $11</a>.</li>
<li>Lantheus Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) stock rose 19.93% after it reported quarterly adjusted <a href="https://www.benzinga.com//node/43968835" target="_blank" rel="noreferrer noopener">EPS and sales above estimates</a>. Truist Securities analyst Richard Newitter maintained a Buy rating and raised the <a href="https://www.benzinga.com/quote/lnth/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from $120 to $127</a>.</li>
<li>Alignment Healthcare, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>) stock gained 19.04% after the company reported better-than-expected Q4 financial results and issued an FY25 outlook. Multiple analyst firms raised their respective <a href="https://www.benzinga.com/quote/ALHC/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecasts on the stock</a>.</li>
<li>VSE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEC#NASDAQ">VSEC</a>) stock jumped 18.49%  after the company reported better-than-<a href="https://www.benzinga.com//node/43990909" target="_blank" rel="noreferrer noopener">expected fourth-quarter results</a>.</li>
</ol>
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/44067124/xpeng-li-auto-and-anheuser-busch-inbev-are-among-top-11-large-cap-gainers-last-week-feb-24-feb-28-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">Xpeng, Li Auto And Nutanix Are Among Top 12 Large-Cap Gainers Last Week (Feb 24-Feb 28): Are The Others In Your Portfolio?</a></li>
<li><a href="https://www.benzinga.com/news/large-cap/25/03/44067248/tesla-palantir-and-microstrategy-are-among-top-12-large-cap-losers-last-week-feb-24-feb-28-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">Tesla, Palantir And MicroStrategy Are Among Top 12 Large-Cap Losers Last Week (Feb 24-Feb 28): Are The Others In Your Portfolio?</a></li>
</ul>

Equities

Mid Cap

ALHC

BRDG

HURN

ROOT

VSEC

Root And ZoomInfo Are Among Top 8 Mid-Cap Gainers Last Week (Feb 24-Feb 28): Are The Others In Your Portfolio?

Truist Securities analyst Richard Newitter maintains Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Buy and raises the price target from $120 to $127.

Truist Securities Maintains Buy on Lantheus Holdings, Raises Price Target to $127

U.S. stocks were mixed, with the Dow Jones falling over 150 points on Wednesday.
Shares of Workday, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) rose sharply during Tuesday's session after the company reported better-than-expected fourth-quarter <a href="https://in.benzinga.com/news/earnings/25/02/43958373/workday-shares-climb-after-q4-report-heres-why">financial results</a>.
Workday reported quarterly earnings of $1.92 per share which beat the analyst consensus estimate of $1.78. Quarterly revenue clocked in at $2.21 billion which beat the analyst consensus estimate of $2.18 billion and is an increase over revenue of $1.92 billion from the same period last year.
Workday shares jumped 6.3% to $271.06 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Porch Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCH#NASDAQ">PRCH</a>) shares jumped 63% to $6.18 following fourth-quarter results.</li>
<li>Gaotu Techedu Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOTU#NYSE">GOTU</a>) gained 32.1% to $3.3450 after the company reported better-than-expected quarterly financial results.</li>
<li>CommScope Holding Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) jumped 22.8% to $6.01 after the company reported better-than-expected quarterly financial results.</li>
<li>ASP Isotopes Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPI#NASDAQ">ASPI</a>) jumped 22.6% to $5.16 after the company announced the start of its commercial production of enriched Carbon-14 at its first aerodynamic separation process enrichment facility.</li>
<li>ACM Research, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACMR#NASDAQ">ACMR</a>) rose 20.2% to $27.57 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Madrigal Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>) shares surged 19.7% to $370.61 after the company reported better-than-expected quarterly EPS and sales.</li>
<li>ZoomInfo Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) gained 19.7% to $11.40 after the company reported better-than-expected fourth-quarter financial results and issued first-quarter revenue guidance above estimates.</li>
<li>CEVA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEVA#NASDAQ">CEVA</a>) gained 19.5% to $38.82.</li>
<li>Lantheus Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) rose 18.4% to $94.76 after reporting quarterly adjusted EPS and sales above estimates.</li>
<li>Huron Consulting Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURN#NASDAQ">HURN</a>) shares gained 18% to $147.96 after the company reported better-than-expected quarterly financial results. Also, multiple firms raised their respective price targets on the stock.</li>
<li>Axon Enterprise, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) rose 17.5% to $583.32 after the company reported better-than-expected fourth-quarter financial results and issued FY24 revenue guidance with its midpoint above estimates.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) gained 16.4% to $53.01 after the company filed its quarterly report.</li>
<li>XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) rose 14.6% to $21.92.</li>
<li>Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) shares gained 11.7% to $620.86 after the company reported better-than-expected second-quarter financial results.</li>
<li>NRG Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) rose 11.3% to $114.04 after the companies announced a venture with TIC to develop rapid electricity generation capacity to support GenAI demand.</li>
<li>First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) gained 9.5% to $161.53 following quarterly results.</li>
<li>Anheuser-Busch InBev SA/NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUD#NYSE">BUD</a>) rose 8.5% to $59.42 after the company reported better-than-expected quarterly earnings and revenues.</li>
<li>Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) shares gained 7.3% to $49.31.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43981181/nvidia-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Nvidia Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Intraday Update

ACMR

ASPI

COMM

FSLR

GSX Techedu Inc. American Depositary Shares

GOTU

HOOD

INTU

MDGL

PRCH

SMCI

WDAY

XPEV

Workday, ACM Research, ZoomInfo Technologies, CEVA, Intuit And Other Big Stocks Moving Higher On Wednesday

Lantheus Holdings shares are trading higher after reporting Q4 Adj. EPS and sales above estimates.

Health Care

Lantheus Forecasts 2025 Revenues Of $1.545B-$1.61B Vs. Consensus Of $1.605B, With Adjusted EPS Of $7.00-$7.20 Vs. $6.95 Est.

Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) reported quarterly earnings of $1.59 per share which beat the analyst consensus estimate of $1.53 by 3.92 percent. This is a 9.14 percent decrease over earnings of $1.75 per share from the same period last year. The company reported quarterly sales of $391.10 million which beat the analyst consensus estimate of $375.43 million by 4.17 percent. This is a 10.48 percent increase over sales of $354.00 million the same period last year.

Lantheus Holdings Q4 2024 Adj EPS $1.59 Beats $1.53 Estimate, Sales $391.10M Beat $375.43M Estimate

Comments

Lantheus Holdings

Intérêt court

Lantheus Holdings (NASDAQ:LNTH) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL